Latest Insights and Progress in the Clinical Management of Elderly Patients with Acute Myeloid Leukemia: From Genetic Advancements to Targeted Treatments DOI Open Access
Pasquale Niscola, Nélida I. Noguera, Valentina Gianfelici

et al.

Published: June 24, 2024

Acute myeloid leukemias (AMLs) are heterogeneous hematologic cancers that occur prevalently in older patients as the result of a complex pathobiology. The clinical outcomes with AML, often unsuitable for intensive chemotherapy and allogeneic stem cell transplantation, generally disappointing. However, recent advances understanding molecular pathogenesis other biological mechanisms recognized AML development progression have changed treatment approach, especially this particularly vulnerable category patients. Indeed, non-intensive biologically tailored approaches, such combining venetoclax hypomethylating agents, therapeutic paradigm field. Moreover, promising compounds strategies currently under advanced development. This article delves into latest management new conceptual frameworks progressively transform practice challenging setting.

Language: Английский

Oxidative stress is two‐sided in the treatment of acute myeloid leukemia DOI Creative Commons
Chenyang Fan, Xiangdong Yang, Lixiang Yan

et al.

Cancer Medicine, Journal Year: 2024, Volume and Issue: 13(9)

Published: May 1, 2024

Abstract Introduction Oxidative stress caused by elevated ROS, as a novel therapeutic mechanism, has been implicated in various tumors including AML. AML cells are chronically under oxidative stress, yet overreliance on ROS production makes tumor increasingly vulnerable to further damage. Reducing the cytotoxic effect of normal while killing leukemia stem cell (LSC) with high levels reactive oxygen species is new challenge for therapy leukemia. Methods By searching literature databases, we summarized recent relevant studies. The relationship genes, signaling pathways, and transcription factors, correlation bone marrow microenvironment autophagy were summarized. In addition, summarize current status research therapeutics. Finally, discuss progress redox resistance Results This review discusses evidence showing link between reactions progression compiles latest findings that will facilitate future biological studies effects associated treatment. Conclusion We believe exploiting this unique property may provide way prevent relapse drug resistance.

Language: Английский

Citations

9
Therapeutic innovations: targeting ROS production in AML with natural and synthetic compounds DOI
Mohammed H. Mohammed,

Raed Fanoukh Aboqader Al-Aouadi,

Subasini Uthirapathy

et al.

Naunyn-Schmiedeberg s Archives of Pharmacology, Journal Year: 2025, Volume and Issue: unknown

Published: March 31, 2025

Language: Английский

Citations

0
3-Bromopyruvate boosts the effect of chemotherapy in acute myeloid leukemia by a pro-oxidant mechanism DOI
Joana Pereira-Vieira, Sara Granja, Sónia Pires Celeiro

et al.

Free Radical Biology and Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: April 1, 2025

Language: Английский

Citations

0
Acute Myeloid Leukemia in Older Patients: From New Biological Insights to Targeted Therapies DOI Creative Commons
Pasquale Niscola, Valentina Gianfelici, Gianfranco Catalano

et al.

Current Oncology, Journal Year: 2024, Volume and Issue: 31(11), P. 6632 - 6658

Published: Oct. 24, 2024

Acute myeloid leukemia (AML) is a heterogeneous blood-related neoplasm that predominantly afflicts older adults with poor prognosis due to their physical condition and the presence of medical accompanying comorbidities, adverse biological disease features, suitability for induction intensive chemotherapy allogenic stem cells transplantation. Recent research into molecular factors contributing development progression has led significant advancements in treatment approaches patients AML. This review article discusses latest therapeutic developments are transforming management AML adults.

Language: Английский

Citations

3
Synergistic Effects of BET Inhibitors and Ferroptosis Inducers via Targeted Inhibition of the BRD4/c-Myc/NRF2 Pathway in AML DOI
Mengjun Zhong, Shuxin Zhong,

Kangjie Qiu

et al.

European Journal of Pharmacology, Journal Year: 2025, Volume and Issue: unknown, P. 177652 - 177652

Published: April 1, 2025

Language: Английский

Citations

0
Characterization of the Biochemical Recurrence Prediction Ability and Progression Correlation of Peroxiredoxins Family in Prostate Cancer Based on Integrating Single‐Cell RNA‐Seq and Bulk RNA‐Seq Cohorts DOI Creative Commons
Shan Tang,

Jinchuang Li,

Wei‐Cheng Tian

et al.

Cancer Medicine, Journal Year: 2025, Volume and Issue: 14(9)

Published: April 25, 2025

ABSTRACT Introduction The peroxiredoxins (PRDXs) family plays a crucial role in balancing reactive oxygen species (ROS) levels tumor cells. However, its potential prognosis and therapy response of prostate cancer (PCa) remains unknown. Methods In this study, we utilized 2 public single‐cell RNA datasets 8 bulk‐RNA to investigate the clinical value six PRDXs members PCa. Expression comparison, biochemical recurrence analysis, analysis were measured. Pathway enrichments predict down‐stream pathway it may involve. vitro experiments used validate function PRDX5 progression castration‐resistant (CRPC) cell lines. Result Among family, was most related advancement cancer. A nomogram integrating expression with features developed better outcomes PCa patients compared 30 published signatures. Immunohistochemistry verify that higher advanced tissue. Gene Set Enrichment Analysis (GSEA) predictive revealed genes mainly relevant ROS Pathway, Mitochondria‐related functions, cellular respiration, oxidative phosphorylation. proliferation assays, determination assay, apoptosis assay together depletion induces via accumulation CRPC Moreover, cells also affects sensitivity ARSI therapy. Conclusion This study offers new evidence for determining is associated grade, poor prognosis, suboptimal multiple therapies within family. Last but not least, our provides insights into precision medicine reference further research on PRDX5.

Language: Английский

Citations

0
Assessment of Total Antioxidant Capacity, 8-Hydroxy-2′-Deoxy-Guanosine, the Genetic Landscape, and Their Associations in BCR::ABL-1-Negative Chronic and Blast Phase Myeloproliferative Neoplasms DOI Open Access
Mihnea‐Alexandru Găman, Cristina Mambet, Ana Iulia Neagu

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(12), P. 6652 - 6652

Published: June 17, 2024

Myeloproliferative neoplasms (MPNs), namely, polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), are clonal stem cell disorders defined by an excessive production of functionally mature terminally differentiated myeloid cells. MPNs can transform into secondary acute leukemia (sAML/blast phase MPN) linked to alterations in the redox balance, i.e., elevated concentrations reactive oxygen species markers oxidative stress (OS), changes antioxidant systems. We evaluated OS 117 chronic 21 sAML cases versus controls measuring total capacity (TAC) 8-hydroxy-2′-deoxy-guanosine (8-OHdG) concentrations. TAC was higher than (p = 0.03), particularly ET 0.04) PMF 0.01). MPL W515L-positive had 0.002) triple-negative patients who treatment expressed lower therapy-free subjects 0.03). 8-OHdG were similar between MPNs, sAML, sAML. noted associations (OR 1.82; p 0.05), 2.36; 0.03) 2.11; but not associated with 1.73; 0.62) or 1.89; 0.49). In conclusion, we detected imbalances based on disease subtype, driver mutations, history.

Language: Английский

Citations

1
Targeting FMS-like tyrosine kinase 3 (FLT3) in acute myeloid leukemia: Novel molecular approaches and therapeutic challenges DOI Open Access

Jan Rataj,

Lukáš Górecki,

Darina Muthná

et al.

Biomedicine & Pharmacotherapy, Journal Year: 2024, Volume and Issue: 182, P. 117788 - 117788

Published: Dec. 28, 2024

Language: Английский

Citations

1
Latest Insights and Progress in the Clinical Management of Elderly Patients with Acute Myeloid Leukemia: From Genetic Advancements to Targeted Treatments DOI Open Access
Pasquale Niscola, Nélida I. Noguera, Valentina Gianfelici

et al.

Published: June 24, 2024

Acute myeloid leukemias (AMLs) are heterogeneous hematologic cancers that occur prevalently in older patients as the result of a complex pathobiology. The clinical outcomes with AML, often unsuitable for intensive chemotherapy and allogeneic stem cell transplantation, generally disappointing. However, recent advances understanding molecular pathogenesis other biological mechanisms recognized AML development progression have changed treatment approach, especially this particularly vulnerable category patients. Indeed, non-intensive biologically tailored approaches, such combining venetoclax hypomethylating agents, therapeutic paradigm field. Moreover, promising compounds strategies currently under advanced development. This article delves into latest management new conceptual frameworks progressively transform practice challenging setting.

Language: Английский

Citations

0